FDA Approves New Oral Treatment for Tenosynovial Giant Cell Tumor

The U.S. FDA has approved PIMJETMI (pimicotinib), an oral CSF1R inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT). This approval targets cases where surgical resection could worsen functional limitation or cause severe morbidity, offering a new therapeutic option for patients with this rare, locally aggressive tumor.